<DOC>
	<DOCNO>NCT01508780</DOCNO>
	<brief_summary>It hypothesize one benefit bosentan relates pulmonary vascular remodeling . The investigator believe study help document nature beneficial change occur patient Pulmonary Arterial Hypertension ( PAH ) response bosentan therapy . In turn , demonstrate change pulmonary vascular structure function accompany clinical improvement .</brief_summary>
	<brief_title>Combined Use Angiography , Optical Coherence Tomography Intravascular Ultrasound Evaluation Pulmonary Vascular Structure Function Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan</brief_title>
	<detailed_description>Subjects Optical coherence tomography ( OCT ) Intravascular Ultrasound ( IVUS ) image right heart catheterization diagnose PAH . Subjects start bosentan follow monthly clinic visit 4 month . At 4 month repeat OCT IVUS imaging .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1. WHO GROUP 1 2 . AGE 1875 3 . Baseline 6min walk distance ( 6MWD ) 200 450 4 . Diagnosed pulmonary artery hypertension right heart catheterization ( Mean Pulmonary Artery Pressure &gt; 25mmHg ) General Exclusion Criteria 1 . Pregnant nursing 2 . Acute chronic illness associate PAH ( collagen vascular disease , human immunodeficiency virus , anorexigen use ) 3 . Previously receive investigational medication , prostanoids , phosphodiesterase inhibitor 4. eGFR &lt; 60 5 . Angina 6 . Syncope 7 . Failing right ventricle 8 . Hemoptysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>